Abstract
7322 Background: CCR in unresectable NSCLC has been superior to sequential approach in several studies. However, concurrence often precludes administration of full-dose chemotherapy. So, induction chemotherapy followed by CCR seems a promising alternative. A phase I study confirmed the feasibility of CCR with biweekly, low-dose, gemcitabine in NSCLC patients (Blackstock, ASTRO99). Methods: Inclusion criteria: unresectable stage III NSCLC, Karnofsky >70,adequate pulmonary, hematologic, renal and liver functions, and planned treated volume <2200cc. Treatment: 3 cycles of cisplatin (100 mg/m2, d1) and gemcitabine (1250 mg/m2, d1&8) q3w followed by CCR (gemcitabine 50 mg/m2 Monday & Thursday and radiotherapy 68.4 Gy, 1.8 Gy qd). After 22 patients included (Group A), unacceptable toxicity was detected and we reduced induction cisplatin dose (70 mg/m2) and CCR gemcitabine dose (35 mg/m2). Another 34 patients (33 eligible, Group B) were included. Results: Toxicity: Non-hematological toxicity of chemo-radiation w...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.